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ABSTRACT
Background: Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed 
during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell 
proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL).
Methods: Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients us-
ing prospectively collected biobanked serum samples. The samples were analyzed using a novel anti-
body-based TK1 immunosorbent assay (ELISA).
Results: The concentrations of S-TK1 were elevated in HL patients compared with healthy controls (medi-
an 0.32 μg/L vs. 0.24 μg/L, P = 0.003). A further increase in S-TK1 was observed during the treatment. The 
S-TK1 concentrations were higher in patients with advanced stage disease, low B-Hb, elevated P-LD and in 
those with B-symptoms. A high ESR correlated with low S-TK1.
Conclusions: The study results suggest that S-TK1, measured using a novel antibody-based assay, has the 
potential to be a biomarker in HL. However, while S-TK1 levels are elevated at baseline compared with 
healthy controls, a limited number of patients and comparatively short follow-up time render reliable 
 conclusions difficult. 
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Thymidine kinase (TK) is an intracellular protein associated with 
DNA synthesis with a potential as a biomarker for cell 
proliferation. Its use has been explored in several tumor diseases 
(1). TK exists in two forms: TK1 is present in cytoplasm in a cell 
cycle dependent manner, while TK2 is located in the 
mitochondria in all cells. TK1 catalyzes the ATP-dependent 
phosphorylation of thymidine to thymidine 5ʹ-monophosphate 
for use in DNA synthesis (2). The expression of thymidine 
kinase-1 (TK1) rises during the late G1 phase, under the control 
of the E2F transcription factor, and remains elevated during the 
S, G2, and M phases. TK1 is subsequently degraded after 
completion of a controlled cell cycle. TK1 concentrations in 
serum are thus indirect indicators of disruption of dividing cells 
through uncontrolled processes such as necrosis.
TK1 is traditionally measured by its enzymatic activity and 
used clinically in non-Hodgkin lymphoma (NHL) but has been 
documented in few studies on Hodgkin lymphoma (HL) (3). 
However, the TK1 molecule is present in serum in different 
complexes, not all are enzymatically active. To address this issue, 
AroCell has developed the novel TK1 210 enzyme-linked 
immunosorbent assay (ELISA) to measure the total content of TK1.
In HL tumors, the malignant Hodgkin and Reed–Sternberg 
(HRS) cells are limited in number, often making histological 
diagnosis difficult for pathologists, while the bulk of the tumor 
consists of normal reactive immune cells. The cell turnover in HL 
would thus be primarily attributed to apoptosis in healthy cells, 
with a controlled turnover of cell cycle-dependent proteins, 
including TK1. Our hypothesis is that TK1 is a more sensitive 
tumor cell turnover marker compared with lactate 
dehydrogenase (LD), commonly used as a biomarker in 
lymphoma. Thus, in this study, we investigated the feasibility of 
using the cell cycle-dependent TK1 as a possible biomarker and 
early treatment predictor in a cohort of HL patients.
Materials and methods
Serum TK1 (S-TK1) was measured in HL patients before and 
during treatment using the AroCell TK 210 ELISA, according to 
the manufacturer’s instructions (AroCell AB, Uppsala, Sweden). 
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The technical specifications of the TK 210 ELISA assay, including 
comparison with the existing Abcam TK1 ELISA assay, have 
previously been published (4). The TK 210 assays show higher 
sensitivity and specificity for hematological malignancies, as 
well as superior discrimination for solid tumors.
Fifty-eight patients with primary or recurrent HL were recruited 
as part of the Uppsala Umeå Comprehensive Cancer Consortium 
(U-CAN) project (5) between September 2010 and November 
2016, and their characteristics are shown in Table 1. The HL cohort 
includes patients treated at Uppsala University Hospital and those 
treated at regional hospitals referred to by Uppsala University 
Hospital. For logistical reasons and changes in routine sampling 
points over time, not all patients have a consistent biobank 
coverage in our cohort. Samples were released from the U-CAN 
biobank for the TK1 analysis under ethical approval (dnr. 
2013/059). For comparison, 269 healthy non-infected controls, 
recruited as part of a health survey, were analyzed. The within-
assay and between-assay imprecisions were found to be between 
5% and 8% CV, respectively (6). A  total of 135 samples were 
analyzed. Baseline samples at diagnosis were available for 39 
patients and seven at the time of relapse. Sequential samples at 
baseline and after two cycles of chemotherapy were available for 
11 patients in the biobanked material.
Non-parametric statistics were applied unless otherwise 
indicated. A P-value of <0.05 was considered statistically 
significant. Multiple regression analysis was applied, with S-TK1 
as the dependent variable and other numerical serum or plasma 
variables as independent variables. Statistical analysis was 
performed using the Medcalc Statistical Software version 19 
(MedCalc Software bvba, Ostend, Belgium; https://www.
medcalc.org; 2019).
Results
The S-TK1 concentrations were elevated in newly diagnosed 
HL  patients when compared with healthy controls (median 
0.32  μg/L vs. 0.24 μg/L, P = 0.003), with a proposed cut-off of 
0.45 g/L based on the upper 97.5 percentile limit of the healthy 
population (Figure 1).
High S-TK1 concentrations correlated with stage and were 
highest in those with stage IV disease (P = 0.006, ANOVA) 
(Figure 2). In addition, high S-TK1 correlated with the presence 
of B-symptoms (P = 0.02) and high international prognostic 
score (IPS) (P = 0.02).
In a multivariate analysis, high S-TK1 concentrations pre-
treatment correlated with low blood hemoglobin (B-Hb) 
(Figure 3), high plasma LD (P-LD) (Figure 4), and low erythrocyte 
sedimentation rate (ESR), but not with other variables included 
in the model, that is, total white blood cells, plasma albumin and 
plasma C-reactive protein. 
During treatment, after two cycles of chemotherapy, the S-TK1 
concentrations increased. The increment was observed in 9 of 11 
patients for whom data were available (P = 0.02, Wilcoxon’s paired 
test; Figure 5). One patient with increment (one of nine) and one 
without increment (one of two) showed an inadequate response 
on interim 2-deoxy-2-[fluorine-18]fluoro-D-glucose positron 
emission tomography–computed tomography (18F-FDG-PET/CT) 
defined as Deauville score ≥ 4 (7), However, all patients remained 
relapse free at the time of analysis.
Correlation with overall or progression-free survival could 
not be determined due to the excellent prognosis of HL and 
limited follow-up time.
Discussion
To our knowledge, this research study presents the only analysis of 
TK1 protein concentrations in the serum of HL patients before and 
Table 1. Patient characteristics.
Variable HL n = 58






Nodular sclerosis 37 (64)
Mixed cellularity 6 (10)
Lymphocyte predominant 2 (3)
Lymphocyte depleted 0 (0)










Adriamycin, Bleomycin, Vinblastine,  
Dacarbazine 
44 (76)
Bleomycin, Etoposide, Adriamycin, 










Treatment related 2 (3)
Disease related 4 (7)
Other 4 (7)
Hemoglobin (g/L) 130.5 (93–172) 
Leukocyte count (× 109 /L) 8.85 (4.3–23.9) 
Lymphocyte count (× 109 /L) 1.5 (0.5–2.8)
Lymphocyte count (%) 15.6 (3.9–35.3)
ESR (mm/h) 23.5 (2–110) 
C-reactive protein (mg/L) 27 (0.7–215)
Albumin (g/L) 35 (22–46) 
LD (µkat/L) 3.1 (2.1–9.7) 
ESR, erythrocyte sedimentation rate; LD, lactate dehydrogenase.
*Classical HL not otherwise specified histology (cHL-NOS).
**ICE, Bendamustin, Rituximab, CEOP.
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Figure 1. Concentrations of Thymidine kinase 1 in serum of patients with Hodgkin lymphoma before treatment and healthy controls, visualized using a 
boxplot showing median value, interquartile range (IQR), and whiskers for Q1 – 1.5 • IQR and Q3 + 1.5 • IQR respectively.
Figure 2. Relation between Thymidine kinase 1 concentrations in serum and disease stage. 
during treatment using a modern antibody-based ELISA assay. In 
our material of newly diagnosed HL patients, we have found 
elevated concentrations of S-TK1 compared with healthy controls, 
with a further increase during treatment. The S-TK1 concentrations 
were higher in patients with advanced stage, low B-Hb, elevated 
P-LD and B-symptoms. However, high S-TK1 correlated with low 
ESR. The correlations to stage, P-LD and B-symptoms as defined by 
the Ann Arbor staging criteria (8) (an unexplained weight loss of 
more than 10% of body weight in less than 6 months, unexplained 
fever with temperatures above 38°C and night sweats) are in 
accordance with previously published results, where TK was 
measured by its enzymatic activity (3).
The value of P-LD in NHL was early recognized (9) and is 
well  established (10). P-LD has been evaluated for HL (11), 
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Figure 3. Relation between Thymidine kinase 1 concentration in serum and hemoglobin. 
Figure 4. Relation between Thymidine kinase 1 concentrations in serum and Lactate Dehydrogenase. 
but  did not pass the test of time, being replaced by IPS (12). 
In  HL tumors, the malignant HRS cells are very few, while the 
bulk of the tumor consists of reactive normal immune cells. It is 
thus likely that the increased concentrations of S-TK1 found in 
our material reflect the increased cell proliferation in a non-HL 
specific manner. B-symptoms as an indirect marker for 
inflammatory activity is an independent prognostic factor for all 
stages. Inflammatory activity as measured by ESR in HL patients 
is only a prognostic marker for early stages (I–IIA). In advanced 
stages (IIB–IVB), a low B-Hb level indicates a chronic inflammatory 
response associated with poorer prognosis. Thus, S-TK more 
accurately reflects the cell turnover by the supporting normal 
immune cells in patients with HL, which is in line with the 
positive correlation with stage. The contradictory correlations 
with low B-Hb and low ESR found in this study could indicate 
that S-TK1 is an independent variable from the inflammatory 
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reactions as measured by ESR in HL. This observation warrants 
further exploration of the role of S-TK1 in the activation of the 
micro-environment by the HRS cells.
The results of this study reveal that the elevation of S-TK1 
concentrations in HL is modest compared with healthy 
controls. Values are considerably higher in patients with 
leukemias, myelomas, myelodysplastic syndromes (4) and 
diffuse large B-cell lymphoma (DLBCL) (data not yet published). 
The dynamics during treatment are also more pronounced in 
DLBCL, where the majority of tumor cells would display an 
unregulated TK1 expression. In comparison, the cell turnover 
in HL tissues largely occurs through apoptotic pathways in 
normal immune cells, producing lower baseline measures. In 
HL, the expression of TK1 is likely tightly controlled in the 
majority of cells, thus TK1 release secondary to chemotherapy 
induced necrosis would be relatively low due to the presence 
of few HRS over all.
While current stratification of patients with HL follows the 
IPS (12), it operates on a population basis. As such it does not 
adequately reflect the individual patient’s prognosis, and thus, 
highlights the need for new biomarkers. S-TK1, which correlated 
with low B-Hb and stage IV in the IPS, is such a potential 
biomarker. However, this feasibility study was not powered to 
show a correlation to survival.
Interim 18F-FDG-PET/CT has been found to be superior in 
predicting outcomes compared with IPS (13) and measures 
response to treatment. While 18F-FDG-PET/CT in most patients 
shows a metabolic response after two cycles of chemotherapy, 
S-TK1 in our material increased during therapy. Given these 
dynamics of S-TK1, early assessment might be useful, ideally 
during the first cycle of chemotherapy.
The mechanism for S-TK1 increase during treatment has 
been established in cell culture experiments measuring TK1 
release in cells treated with doxorubicin (14). Chemotherapy 
agents, such as doxorubicin and dacarbazine, used in HL are 
known to halt the cell cycle in the G2/M phases, where TK1 is 
actively expressed. TK1 has also been shown to peak on day 1 
after starting treatment in NHL patients (15). The increase of 
TK1 during therapy in our material is consistent with these 
findings.
As previous studies have shown that the TK1 values vary over 
time in relation to the administration of chemotherapy, further 
studies with repeated analyses are needed to ascertain the best 
time to analyze TK1 in relation to the administration of 
chemotherapy. U-CAN samples are collected either midcycle or 
prior to cycle 3. TK1 concentrations are thus collected at their 
lowest point in relation to chemotherapy, which strengthens 
the argument for TK1 as a possible biomarker.
In conclusion, our analysis suggests that relative change in 
TK1, before and after initiation of chemotherapy could be a 
potential biomarker in HL; however, further studies are needed 
to determine the role of TK1 in relation to chemotherapy 
administration.
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Figure 5. Linked Thymidine kinase 1 concentration changes in serum pre-treatment and during treatment. 
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